Table 3 Multivariable Cox regression analysis of the impact of different variables on the leukemia-free survival and overall survival of patients with myelodysplastic syndromes/neoplasms.

From: Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

View full size image

  1. Note: Only 17 patients (2.7%) were categorized as IPSS-M very low risk and there was no inter-group difference between IPSS-M very low and low risk subgroups in both OS and LFS; accordingly, we put IPSS-M very low and low groups together.
  2. CI confidence interval, HR hazard ratio, HSCT allogeneic hematopoietic stem cell transplantation, h hypoplastic, IPSS-M molecular international prognostic scoring system, LFS leukemia-free survival, MDS myelodysplastic syndromes/neoplasms, OS overall survival.
  3. P values of <0.05 are statistically significant.
  4. *As continuous variables analysis.
  5. †Low-risk MDS included MDS with del(5q), MDS with mutated SF3B1, MDS, NOS with MLD.
  6. ‡MDS patients with EB and blast percentage < 5% in peripheral blood.
  7. §MDS/AML with MDS-related gene mutations, MDS-related cytogenetic abnormalities, or not otherwise specified. Patients with MDS with EB and blast percentage ≥ 5% in peripheral blood were included in this group.
  8. MDS or MDS/AML with mutated TP53, defined by International Consensus Classification.
Back to article page